The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•4 May 2026•

1 min read

Twist Bioscience Shares Fall as Widening Losses Offset AI-Driven Sales Growth

Key Facts

1Twist Bioscience reported its fiscal 2026 second-quarter financial results, leading to a decline in its share price.

2AI-driven demand boosted the company's sales, but net losses widened during the period.

Twist Bioscience (TWST) reported its fiscal second-quarter 2026 financial results, revealing a complex performance profile that led to a decline in share price. While AI-driven demand significantly boosted the company's top-line sales, net losses widened during the period, missing investor expectations for narrowing deficits. The inability to translate revenue growth into improved bottom-line results weighed heavily on market sentiment. Analysts noted that despite the strong tailwinds from the AI sector, operational costs continue to challenge the firm's path to profitability. Consequently, the stock faced immediate downward pressure as investors reassessed the company's fiscal trajectory. This report highlights the ongoing struggle within the biotechnology sector to balance aggressive innovation with financial sustainability.